<DOC>
	<DOCNO>NCT00445939</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy safety adalimumab induction clinical remission Japanese subject Crohn 's disease .</brief_summary>
	<brief_title>A Study Adalimumab Induction Clinical Remission Japanese Subjects With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Crohn 's Disease Activity Index ( CDAI ) score &gt; = 220 &lt; = 450 If subject previously administer infliximab , subject discontinue use due loss response intolerance infliximab therapy Ulcerative colitis indeterminate colitis History cancer , lymphoma , leukemia lymphoproliferative disease , active tuberculosis ( TB ) , Human immunodeficiency virus ( HIV ) Body weight 30 kg Surgical bowel resection within past 6 month Females pregnant breastfeed consider become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>